Phillips-Medisize Wins Sustainability Award

On World Environment Day, the Sustainability Advisory Committee and City Council President of Eau Claire, Wisconsin, recognized Phillips-Medisize as the recipient of their 2017 Sustainable Eau Claire Award. Companies, organizations, and individuals are all considered for these awards, which honor a push towards a healthier, more “sustainable,” Eau Claire. This Molex company won in the category of “Clean Up or Beautification,” and recently completed projects, including a wildlife habitat and monarch joint venture.

Of the recognition, Matt Jennings, Chairman and CEO of Phillips-Medisize, said in a statement, “We are honored to receive this award. It represents how Phillips-Medisize, and our people, are able to contribute positively to the environment. This is a reflection of the efforts that our people put forth every day.”

Phillips-Medisize receives the 2017 Sustainable Eau Claire Award

Skipta and Continuum Clinical Combine Forces

Skipta recently joined forces with Continuum Clinical to create a new research entity called The Center for Observational Research. The center is designed to connect physicians and allow for secured environment “real-world research opportunities.” Those outside of the usual clinical trials areas can be sought out using crowdsourcing and research sponsors, allowing for a greater range of areas of study. At press time, the center is already actively researching immunology, oncology, dermatology, and gastroenterology. Continuum Clinical President, Jeff Trotter, believes the joint center will create a new “era in this field.”

John Ciccio, President of Skipta, shares Trotter’s enthusiasm, stating, “Skipta is thrilled to be working with Continuum Clinical, furthering our mission to support the professional, education, and economic development of our members by bringing to them the latest study opportunities directly within the Skipta community. The Center for Observational Research adds another dimension to the type of content we offer to members, and we know it’s content that they want.”

Ophthalmic Partnership to Help Patients

Genentech recently signed a license agreement with Vital Art and Science, LLC, which allows Vital Art and Science’s mVT App service utilization in their ophthalmology clinical studies. Genentech hopes using the data from the App service will improve patient/healthcare provider communications.

On the license agreement, Mike Bartlett, President and CEO of Vital Art and Science, said in a statement, “This agreement is the successful continuation of an ongoing collaboration between the teams at Vital Art and Science and Genentech. We believe that Genentech, a leader in ophthalmic drug development, is a strong partner for the mVT Service that will drive more retina specialists and other ophthalmic drug companies to adopt as the next industry standard for vision monitoring in between office assessment.”

New Territory: Provider Market Access

Provider Market Access, a one-of-a-kind “suite of advanced analytics,” was recently launched by Zephyr Health and Decision Resources Group (DRG), and is available within the Zephyr Illuminate platform. This suite utilizes DRG’s market access data with the other data sources available in Zephyr Illuminate to impart clear market insights central to the provider.

Lance Scott, President and CEO of Zephyr Health, addressed the importance of the new platform, stating, “These groundbreaking capabilities help maximize sales opportunities and accelerate brand performance by contextualizing market access status into actionable insights.”

Ads

You May Also Like

Precision Medicine: The Future of Medicine?

Doctors have long recognized that the outcomes from treating the same disease can vary ...

Industry Briefs

POLLSTERS MERGE Survey Sampling International (SSI) and Opinionology announced that they have received regulatory ...

Healthcare Watch September 2015

Med Device: Remote-Controlled Drugs? In the future, taking your daily dose of medication may ...